Cart summary

You have no items in your shopping cart.

JANEX-1

SKU: orb1306654

Description

JANEX-1

Research Area

Cardiovascular Research, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−
JANEX-1

Key Properties

−
CAS Number202475-60-3
MW297.31
Purity98.03%
FormulaC16H15N3O3
SMILESCOc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC
TargetJAK
Solubility10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.73 mM);DMSO:55 mg/mL (184.99 mM)

Bioactivity

−
Target IC50
JAK3:78 μM
In Vivo
JANEX-1 is administered in doses from 5 to 100 mg/kg, showing a dose-response relationship with an ED50 of 7.44 mg/kg, significantly reducing CPK and LDH levels in mice. These mice also exhibit a notably smaller infarct size (30.16±2.79%) compared to I/R-operated mice (65.64±3.76%). JANEX-1, also known as WHI-P131, is quickly absorbed, reaching peak plasma concentration in roughly 24.7±1.7 minutes, and has a short elimination half-life of 45.6±5.5 minutes. Despite the maximum plasma concentration being only half of what is observed with intravenous (i.v.) administration at the same dose, intraperitoneal (i.p.) bioavailability stands at 94.6%, with systemic exposure levels (AUC) closely matching those seen after i.v. injection (17.1±2.2 μM·h versus 18.1±1.2 μM·h).
Read more...
In Vitro
JANEX-1 (WHI-P131) exhibits strong inhibitory activity against JAK3 with an IC50 value of 78 μM, while showing no inhibitory effects on JAK1, JAK2, and various tyrosine kinases including SYK, BTK, LYN, and the insulin receptor kinase, even at concentrations up to 350 μM. It specifically induces apoptosis in human leukemia cell lines expressing JAK3 (NALM-6 and LC1;19) without affecting melanoma (M24-MET) or squamous carcinoma (SQ20B) cells. Furthermore, WHI-P131 effectively suppresses the clonogenic growth of several JAK3-positive leukemia cell lines (DAUDI, RAMOS, LC1;19, NALM-6, MOLT-3, and HL-60) in a concentration-dependent manner, with EC50 values of 24.4 μM and 18.8 μM for NALM-6 and DAUDI cells respectively, achieving more than 99% inhibition of colony formation at 100 μM. However, it does not impede the clonogenic proliferation of JAK3-negative cancer cell lines such as BT-20 breast cancer, M24-MET melanoma, or SQ20B squamous carcinoma.
Read more...
Cell Research
JANEX-1 (WHI-P131) is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 0.1%) before use. The following cell lines are used in various biological assays: NALM-6 (pre-B-ALL), LC1;19 (pre-B-ALL), DAUDI (B-ALL), RAMOS (B-ALL), MOLT-3 (T-cell ALL), HL60 (acute myelogenous leukemia), BT-20 (breast cancer), M24-MET (melanoma), SQ20B (squamous cell carcinoma), and PC3 (prostate cancer). These cell lines are maintained in culture. Cells are seeded in six-well tissue culture plates at a density of 50×104 cells/well in a treatment medium containing various concentrations of JANEX-1 (0.1, 0.2, 0.3, 0.4 and 0.5 nM) and incubated for 24-48 h at 37°C in a humidified 5% CO2 atmosphere. Cells are examined for apoptotic changes after treatment with JANEX-1 by the in situ TdT-mediated dUTP end-labeling assay using the ApopTag apoptosis detection kit.
Read more...

Storage & Handling

−
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
WHI-P131, WHI-P-131, WHI-P 131, Inhibitor, JAK3, Jak3 inhibitor I, JANEX1, JANEX-1, JANEX 1, Janus kinase, JAK, inhibit

Similar Products

−
  • JANEX-1 hydrochloride

    JANEX-1 hydrochloride [orb2646118]

    188829-39-2

    333.77

    C16H16ClN3O3

    50 mg, 25 mg, 100 mg
  • JANEX-1-M

    JANEX-1-M [orb2814947]

    406484-24-0

    283.28

    C15H13N3O3

    50 mg, 10 mg
  • WHI-P131

    WHI-P131 [orb1225745]

    >98% (HPLC)

    202475-60-3

    297.31

    C16H15N3O3

    1 g, 500 mg, 25 mg, 2 mg, 5 mg, 50 mg, 100 mg, 10 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID
3794 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

JANEX-1 (orb1306654)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

2 mg
$ 70.00
5 mg
$ 90.00
1 ml x 10 mM (in DMSO)
$ 100.00
10 mg
$ 130.00
25 mg
$ 190.00
50 mg
$ 260.00
100 mg
$ 370.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

info@biorbyt.com

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor